PMID- 15374997
OWN - NLM
STAT- MEDLINE
DCOM- 20041104
LR  - 20201215
IS  - 0008-5472 (Print)
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Linking)
VI  - 64
IP  - 18
DP  - 2004 Sep 15
TI  - Dendritic cells strongly boost the antitumor activity of adoptively transferred T 
      cells in vivo.
PG  - 6783-90
AB  - Dendritic cells (DCs) have been well characterized for their ability to initiate 
      cell-mediated immune responses by stimulating naive T cells. However, the use of 
      DCs to stimulate antigen-activated T cells in vivo has not been investigated. In 
      this study, we determined whether DC vaccination could improve the efficacy of 
      activated, adoptively transferred T cells to induce an enhanced antitumor immune 
      response. Mice bearing B16 melanoma tumors expressing the gp100 tumor antigen 
      were treated with cultured, activated T cells transgenic for a T-cell receptor 
      specifically recognizing gp100, with or without concurrent peptide-pulsed DC 
      vaccination. In this model, antigen-specific DC vaccination induced cytokine 
      production, enhanced proliferation, and increased tumor infiltration of 
      adoptively transferred T cells. Furthermore, the combination of DC vaccination 
      and adoptive T-cell transfer led to a more robust antitumor response than the use 
      of each treatment individually. Collectively, these findings illuminate a new 
      potential application for DCs in the in vivo stimulation of adoptively 
      transferred T cells and may be a useful approach for the immunotherapy of cancer.
FAU - Lou, Yanyan
AU  - Lou Y
AD  - Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson 
      Cancer Center, Houston, Texas 77030, USA.
FAU - Wang, Gang
AU  - Wang G
FAU - Lizee, Gregory
AU  - Lizee G
FAU - Kim, Grace J
AU  - Kim GJ
FAU - Finkelstein, Steven E
AU  - Finkelstein SE
FAU - Feng, Chiguang
AU  - Feng C
FAU - Restifo, Nicholas P
AU  - Restifo NP
FAU - Hwu, Patrick
AU  - Hwu P
LA  - eng
GR  - Z01 BC010763-01/Intramural NIH HHS/United States
GR  - Z99 CA999999/Intramural NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Cancer Vaccines)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PMEL protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (Pmel protein, mouse)
RN  - 0 (gp100 Melanoma Antigen)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Lymphocyte Activation/immunology
MH  - Melanoma, Experimental/immunology/therapy
MH  - Membrane Glycoproteins/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neoplasm Proteins/immunology
MH  - Peptide Fragments/immunology
MH  - T-Lymphocytes/*immunology
MH  - gp100 Melanoma Antigen
PMC - PMC2241750
MID - NIHMS38348
EDAT- 2004/09/18 05:00
MHDA- 2004/11/05 09:00
PMCR- 2008/02/13
CRDT- 2004/09/18 05:00
PHST- 2004/09/18 05:00 [pubmed]
PHST- 2004/11/05 09:00 [medline]
PHST- 2004/09/18 05:00 [entrez]
PHST- 2008/02/13 00:00 [pmc-release]
AID - 64/18/6783 [pii]
AID - 10.1158/0008-5472.CAN-04-1621 [doi]
PST - ppublish
SO  - Cancer Res. 2004 Sep 15;64(18):6783-90. doi: 10.1158/0008-5472.CAN-04-1621.